The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Tue., Dec. 6, 7:54 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #59. Horizon Pharma USA, Inc. POZEN's U.S. Rights for VIMOVO

Acquirer: Horizon Pharma USA, Inc. (HZNP)
Acquiree: POZEN's U.S. Rights for VIMOVO (POZN)
Details: POZEN Inc. (NASDAQ:POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that AstraZeneca AB and Horizon Pharma USA, Inc. (NASDAQ:,HZNP) have entered into an agreement for Horizon to acquire the U.S. rights for VIMOVO (naproxen / esomeprazole magnesium) delayed release tablets. Under the terms of the agreement, POZEN will continue to receive a 10% royalty on Net Sales of products sold in the United States, with guaranteed annual minimum royalty payments of $5 million in 2014, and $7.5 million each year thereafter, provided that the patents owned by POZEN which cover VIMOVO are in effect and no generic forms of VIMOVO are on the market. Also under the agreement, Horizon has assumed AstraZeneca's right to lead the on-going Paragraph IV litigation for VIMOVO and will assume all patent-related defense costs relating to such litigation, including reimbursement for a specified amount of the cost of counsel retained by POZEN. AstraZeneca will continue to have rights to commercialize VIMOVO outside of the United States.

Horizon Therapeutics is focused on researching, developing and commercializing medicines that address the needs for people with rare and rheumatic diseases. Co. has two segments, the orphan segment and the inflammation segment. The Orphan segment includes: TEPEZZA, which is indicated for the treatment of thyroid eye diseas; KRYSTEXXA, which is indicated for the treatment of uncontrolled gout; and PROCYSBI, which is indicated for nephropathic cystinosis. The Inflammation segment includes: PENNSAID 2% w/w, which is indicated for the treatment of pain of osteoarthritis (OA), of the knee(s); and DUEXIS, which is indicated for the relief of signs and symptoms of rheumatoid arthritis and OA.

HZNP SEC Filing Email Alerts Service


Open the HZNP Page at The Online Investor »

Horizon Therapeutics is focused on researching, developing and commercializing medicines that address the needs for people with rare and rheumatic diseases. Co. has two segments, the orphan segment and the inflammation segment. The Orphan segment includes: TEPEZZA, which is indicated for the treatment of thyroid eye diseas; KRYSTEXXA, which is indicated for the treatment of uncontrolled gout; and PROCYSBI, which is indicated for nephropathic cystinosis. The Inflammation segment includes: PENNSAID 2% w/w, which is indicated for the treatment of pain of osteoarthritis (OA), of the knee(s); and DUEXIS, which is indicated for the relief of signs and symptoms of rheumatoid arthritis and OA.

HZNP SEC Filing Email Alerts Service


Open the POZN Page at The Online Investor »

Company Name: 
Horizon Therapeutics Plc
Website: 
www.horizontherapeutics.com
Sector: 
Biotechnology
Number of ETFs Holding HZNP: 
60
Total Market Value Held by ETFs: 
$2.37B
Total Market Capitalization: 
$22.86B
% of Market Cap. Held by ETFs: 
10.37%
Company Name: 
Pozen Inc.
Website: 
www.pozen.com
Sector: 
Drugs & Pharmaceuticals
 

Quotes delayed 20 minutes

Email EnvelopeFree Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Drugs & Pharmaceuticals M&A - Slide 59 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.